ARTICLE | Clinical News
Actimmune: ITMN said the Data Safety Monitoring Board (DSMB) recommended continuation of the company's international 330-patient Phase III trial of Actimmune to
January 22, 2002 8:00 AM UTC
InterMune Pharmaceuticals Inc. (ITMN), Brisbane, Calif. Product: Actimmune Business: Pulmonary Therapeutic category: Immune modulation Target: Unknown Description: Interferon gamma-1b Indication: Tre...